DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Mercury Laboratories Ltd (MERCURYLAB) share price today?

Mercury Laboratories Ltd (MERCURYLAB) is trading at ₹858.35 on the BSE, down 0.05% on the day. Source: DocStoX.

What is the PE ratio of Mercury Laboratories Ltd?

Mercury Laboratories Ltd has a price-to-earnings (PE) ratio of 32.8 in the Healthcare sector.

What is the market capitalisation of Mercury Laboratories Ltd?

Mercury Laboratories Ltd has a market capitalisation of approximately ₹108 crore.

Mercury Laboratories Ltd

MERCURYLAB·BSE·Healthcare

₹858.35▼ -0.45 (-0.05%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹836.00

₹898.00

52W₹621

₹97667%

Open

₹885.00

High

₹898.00

Low

₹836.00

Prev Close

₹858.80

Volume

VWAP

₹858.31

Snapshot

Key fundamentals

Market Cap

₹108 Cr

P/E Ratio

32.80Fair

P/B Ratio

1.77

EPS

₹26.17

Book Value

₹484.00

ROE

5.87%Weak

ROCE

8.94%Weak

Dividend Yield

0.41%

Debt / Equity

0.14Low

Face Value

₹10.00

52W High

₹976.00

52W Low

₹620.55

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

None moatHigh uncertainty

Fair value estimate

₹497

▼ 42.1%downside

Trading at ₹858 — 42% above our estimate

BearFair valueBull

₹422₹497₹673

/100

Business quality — Watch the fundamentals

Growth 50Profitability 8Efficiency 5Valuation 68

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (6%)

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Weak returns on equity (6%)

How we got there

Fair value methods

Residual income

6% ROE fading to 12% over ~3 yrs, on ₹484 book

₹448

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹673

Analyst target

No analyst coverage

—

Blended fair value₹497

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Weak returns on equity (6%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

32.8Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

5.9%Weak

Above 15% is considered healthy for Indian equities

ROCE

8.9%Weak

Above 18% means capital is working hard

Debt/Eq

0.14Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹108 Cr

P/B

1.77

EPS

₹26.17

Div Yield

0.41%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Reasonable

P/E 32.8×

Growth

Slow

+0% rev CAGR

Profitability

Modest

5.9% ROE

Financial health

Rock solid

D/E 0.14

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹84,973 Cr

Trades24

VWAP₹858.31

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+0.3%

+2.0%

10Y

+4.8%

Profit

-3.7%

-1.4%

10Y

+2.4%

EPS

-3.6%

-1.3%

10Y

+2.5%

Profile

Cons

The company has delivered a poor sales growth of 2.05% over past five years.
Company has a low return on equity of 8.84% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

74%

Promoter

Promoters

73.7%0.00

Public

16.6%0.00

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

9.8%

Total shareholders

1,328+12 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter73.66%

Public16.58%

Others9.76%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical items of gyno and pediatrics.[1]